Search results
Results from the WOW.Com Content Network
Defibrotide, sold under the brand name Defitelio, is a mixture of single-stranded oligonucleotides that is purified from the intestinal mucosa of pigs. It is used to treat veno-occlusive disease of the liver of people having had a bone marrow transplant, with different limitations in the US and the European Union.
Torsades de pointes is the most serious side effect of dofetilide therapy. The incidence of torsades de pointes is 0.3-10.5% and is dose-related, with increased incidence associated with higher doses.
DHEA (Dehydroepiandrosterone) – a steroid hormone that has been promoted in supplement form for its claimed cancer prevention properties; there is no scientific evidence to support these claims. [152] Di Bella Therapy – a cocktail of vitamins, drugs and hormones devised by Luigi di Bella (1912–2003) and promoted as a cancer treatment ...
Ensure women are aware of their cancer profile early. "All women should know their cancer risk profile by the age of 30," Litvack says. "We all need to be in control of our own health, having the ...
The Autoimmune Protocol (AIP) diet is an elimination diet designed to help reduce inflammation, manage symptoms and improve quality of life for people with autoimmune diseases.
ovarian cancer, malignant ascites, gastric cancer cBR96-doxorubicin immunoconjugate: mab: humanized: Lewis-Y antigen: cancer Cedelizumab [47] mab: humanized: CD4: prevention of organ transplant rejections, treatment of autoimmune diseases Cemiplimab [32] Libtayo: mab: human: PD-1: Y: cutaneous squamous cell carcinoma Cergutuzumab amunaleukin ...
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
Relugolix was approved for the treatment of uterine fibroids in Japan in January 2019. [12] [13] It was the second orally active GnRH antagonist to be introduced for medical use, following elagolix (brand name Orilissa) in July 2018. [12] [17] Relugolix was approved for the treatment of prostate cancer in the United States on 18 December 2020 ...